Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
TENX

TENX - Tenax Therapeutics Inc Stock Price, Fair Value and News

$14.04-0.71 (-4.81%)
Market Closed

83/100

TENX

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

83/100

TENX

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$22.05

Target 3M

$18.38

Target 6M

$19.84

TENX Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

TENX Price Action

Last 7 days

-9.7%

Last 30 days

15.3%

Last 90 days

87.9%

Trailing 12 Months

126.1%

TENX RSI Chart

TENX Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

TENX Valuation

Market Cap

87.7M

Price/Earnings (Trailing)

-2.02

Price/Sales (Trailing)

0.44

Price/Free Cashflow

-3.39

TENX Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$22.05

Target 3M

$18.38

Target 6M

$19.84

TENX Fundamentals

TENX Revenue

Revenue (TTM)

100.3M

TENX Earnings

Earnings (TTM)

-43.3M

Earnings Growth (Yr)

-298.99%

Earnings Growth (Qtr)

-45.7%

TENX Profitability

Return on Equity

-45.03%

Return on Assets

-42.14%

Free Cashflow Yield

-29.54%

TENX Investor Care

Shares Dilution (1Y)

83.15%

Diluted EPS (TTM)

1.16

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20250000
202442.9M071.6M100.3M
20237.1M9.4M11.8M14.1M
2015049.3K4.7M0
2014444.9K263.0K00
20131.1M1.2M1.1M625.5K
2012346.3K381.1K593.7K1.0M
20110104.1K156.6K224.7K
20100000
Get all data in R, Python etc through our Historical Stock Data APIs

About Tenax Therapeutics Inc

TENX
Tenax Therapeutics, Inc. develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension. It develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is based in Chapel Hill, North Carolina.
 CEO
 WEBSITEtenaxthera.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES7

Tenax Therapeutics Inc Frequently Asked Questions

TENX is the stock ticker symbol of Tenax Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Tenax Therapeutics Inc is 87.66 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check TENX's fair value in chart for subscribers.

The fair value guage provides a quick view whether TENX is over valued or under valued. Whether Tenax Therapeutics Inc is cheap or expensive depends on the assumptions which impact Tenax Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for TENX.

As of Wed Jan 28 2026, TENX's PE ratio (Price to Earnings) is -2.02 and Price to Sales (PS) ratio is 0.44. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. TENX PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, Tenax Therapeutics Inc has provided -0.581 (multiply by 100 for percentage) rate of return.